Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

706
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
706
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

7.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.9K
Coagulation01:09

Coagulation

6.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bleeding risk after kidney biopsy with platelet inhibition.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Modulation of the bone marrow microenvironment by acute B-cell lymphoblastic leukemia-derived large oncosomes.

Blood advances·2026
Same author

Type I interferon-activated NK cells control polycythemia vera in vivo.

Blood·2026
Same author

Chronic Erythrocyte NO Production Accelerates Atherosclerosis by Increasing SMC De Novo Lipogenesis.

Circulation research·2026
Same author

Iptacopan in IgA Nephropathy - Final 24-Month Data.

The New England journal of medicine·2026
Same author

Increased albuminuria is highly prevalent in the general population: prevalence of CKD in the Gutenberg Health Study.

Clinical kidney journal·2026

Related Experiment Video

Updated: Jul 7, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.0K

Targeting the tissue factor coagulation initiation complex prevents antiphospholipid antibody development.

Nadine Müller-Calleja1,2, Kristin Grunz1, T Son Nguyen1

  • 1Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany.

Blood
|December 24, 2023
PubMed
Summary

Targeting the tissue factor (TF) initiation complex with nematode anticoagulant protein c2 (NAPc2) prevents antiphospholipid antibody (aPL)-induced thrombosis. NAPc2 also inhibits aPL development in models of viral infection and lupus, suggesting a novel therapeutic strategy.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.7K
Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

514

Related Experiment Videos

Last Updated: Jul 7, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.0K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.7K
Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

514

Area of Science:

  • * Immunology
  • * Thrombosis
  • * Molecular Biology

Background:

  • * Antiphospholipid antibodies (aPL) are a major cause of acquired thrombophilia in antiphospholipid syndrome (APS).
  • * Current interventions for APS primarily focus on anticoagulation, with unmet needs for preventing autoimmune aPL development.
  • * Lipid-reactive aPL recognize lysobisphosphatidic acid presented by the endothelial protein C receptor, activating TF-dependent prothrombotic signaling.

Purpose of the Study:

  • * To investigate the therapeutic potential of inhibiting the tissue factor (TF) coagulation initiation complex with nematode anticoagulant protein c2 (NAPc2).
  • * To explore the role of TF and NADPH oxidase in aPL development and associated prothrombotic effects.
  • * To evaluate NAPc2's efficacy in preventing aPL-induced thrombosis and inflammation in preclinical models.

Main Methods:

  • * Administration of NAPc2 to mice with COVID-19-derived aPL or experimentally induced APS.
  • * Assessment of monocyte activation, reactive oxygen species production, and interferon-α secretion.
  • * Evaluation of NAPc2 treatment in murine cytomegalovirus infection and MRL-lpr lupus models.

Main Results:

  • * NAPc2 inhibited prothrombotic effects of COVID-19-derived aPL and aPL-induced monocyte activation.
  • * NAPc2 suppressed TF cytoplasmic domain-dependent reactive oxygen species production and interferon-α secretion.
  • * Short-term NAPc2 intervention prevented persistent aPL development during latent viral infection.
  • * NAPc2 treatment attenuated lupus pathology, dendritic cell activation, and aPL production in MRL-lpr mice.

Conclusions:

  • * A convergent TF-dependent mechanism underlies aPL development in viral infections and autoimmune diseases.
  • * Specific inhibition of the TF initiation complex with NAPc2 demonstrates therapeutic benefits beyond anticoagulation.
  • * Targeting the TF initiation complex represents a promising strategy for preventing aPL development and associated pathologies.